Recro Pharma (REPH) Trading 10% Higher

Share on StockTwits

Recro Pharma Inc (NASDAQ:REPH)’s share price traded up 10% on Wednesday . The company traded as high as $8.19 and last traded at $8.82. 35,919 shares traded hands during mid-day trading, a decline of 67% from the average session volume of 107,960 shares. The stock had previously closed at $8.02.

A number of equities analysts have weighed in on the stock. Zacks Investment Research cut shares of Recro Pharma from a “hold” rating to a “sell” rating in a research report on Tuesday, May 15th. ValuEngine raised shares of Recro Pharma from a “sell” rating to a “hold” rating in a research report on Tuesday. Oppenheimer set a $18.00 price objective on shares of Recro Pharma and gave the company a “buy” rating in a research report on Wednesday. BidaskClub raised shares of Recro Pharma from a “hold” rating to a “buy” rating in a research report on Thursday, May 24th. Finally, Roth Capital set a $9.00 price objective on shares of Recro Pharma and gave the company a “buy” rating in a research report on Saturday, May 26th. Three research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. The company currently has an average rating of “Buy” and an average target price of $12.63.

The stock has a market capitalization of $132.18 million, a P/E ratio of -4.24 and a beta of -0.81. The company has a current ratio of 1.59, a quick ratio of 1.42 and a debt-to-equity ratio of 2.22.

Recro Pharma (NASDAQ:REPH) last released its quarterly earnings data on Tuesday, August 7th. The specialty pharmaceutical company reported ($0.62) earnings per share for the quarter, topping the consensus estimate of ($1.34) by $0.72. The firm had revenue of $21.74 million for the quarter, compared to analyst estimates of $16.81 million. Recro Pharma had a negative net margin of 75.19% and a negative return on equity of 144.84%. sell-side analysts predict that Recro Pharma Inc will post -2.5 earnings per share for the current fiscal year.

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Jump Trading LLC acquired a new stake in Recro Pharma during the first quarter worth about $124,000. Citadel Advisors LLC acquired a new stake in Recro Pharma during the first quarter worth about $126,000. Cubist Systematic Strategies LLC acquired a new stake in Recro Pharma during the first quarter worth about $139,000. Oppenheimer & Co. Inc. acquired a new stake in Recro Pharma during the second quarter worth about $154,000. Finally, Monarch Partners Asset Management LLC acquired a new stake in Recro Pharma during the second quarter worth about $178,000. Hedge funds and other institutional investors own 55.86% of the company’s stock.

About Recro Pharma (NASDAQ:REPH)

Recro Pharma, Inc, a specialty pharmaceutical company, engages in developing non-opioid products for the treatment of acute pain primarily in the United States. The company's lead product candidate includes injectable meloxicam, which completed pivotal phase III clinical trials for the treatment of post-operative pain.

Recommended Story: What is the NASDAQ?

Receive News & Ratings for Recro Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recro Pharma and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply